Asensus Surgical Inc
F:2TX
Asensus Surgical Inc
F:2TX
Price:
0.3
EUR
-1.64%
Market Cap:
€81.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Asensus Surgical Inc
F:2TX
|
US |
|
Kitoku Shinryo Co Ltd
TSE:2700
|
JP |
|
ARE Holdings Inc
OTC:AHHLF
|
JP |
|
1mage Software Inc
OTC:ISOL
|
US |
|
F3 Uranium Corp
OTC:FUUFF
|
CA |
Balance Sheet
Balance Sheet Decomposition
Asensus Surgical Inc
Asensus Surgical Inc
Balance Sheet Decomposition is not available for
Asensus Surgical Inc
Asensus Surgical Inc
Balance Sheet
Asensus Surgical Inc
Asensus Surgical Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
35
|
39
|
24
|
91
|
21
|
10
|
16
|
18
|
6
|
17
|
|
| Cash |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
35
|
37
|
24
|
91
|
21
|
10
|
16
|
18
|
6
|
17
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
52
|
0
|
0
|
80
|
64
|
4
|
|
| Total Receivables |
0
|
1
|
2
|
3
|
9
|
3
|
4
|
2
|
3
|
4
|
|
| Accounts Receivables |
0
|
0
|
1
|
2
|
9
|
1
|
1
|
1
|
2
|
4
|
|
| Other Receivables |
0
|
1
|
1
|
2
|
0
|
3
|
3
|
1
|
1
|
0
|
|
| Inventory |
0
|
4
|
8
|
11
|
11
|
11
|
10
|
9
|
8
|
7
|
|
| Other Current Assets |
1
|
6
|
4
|
8
|
9
|
4
|
4
|
4
|
5
|
5
|
|
| Total Current Assets |
36
|
49
|
38
|
113
|
102
|
28
|
34
|
113
|
87
|
36
|
|
| PP&E Net |
3
|
4
|
6
|
7
|
6
|
7
|
12
|
16
|
15
|
14
|
|
| PP&E Gross |
0
|
4
|
6
|
7
|
6
|
7
|
12
|
16
|
15
|
14
|
|
| Accumulated Depreciation |
0
|
5
|
7
|
9
|
11
|
11
|
14
|
10
|
13
|
16
|
|
| Intangible Assets |
2
|
63
|
53
|
53
|
51
|
31
|
22
|
10
|
2
|
1
|
|
| Goodwill |
94
|
131
|
69
|
71
|
80
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
37
|
4
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
11
|
7
|
1
|
9
|
10
|
10
|
9
|
7
|
|
| Other Assets |
94
|
131
|
69
|
71
|
80
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
135
N/A
|
249
+84%
|
176
-29%
|
250
+42%
|
239
-4%
|
75
-69%
|
78
+5%
|
187
+138%
|
116
-38%
|
59
-49%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
5
|
4
|
4
|
4
|
4
|
2
|
3
|
3
|
4
|
|
| Accrued Liabilities |
2
|
7
|
8
|
10
|
9
|
9
|
6
|
6
|
7
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
7
|
8
|
5
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
13
|
11
|
10
|
8
|
1
|
1
|
1
|
1
|
0
|
|
| Total Current Liabilities |
4
|
31
|
31
|
29
|
22
|
13
|
10
|
10
|
10
|
13
|
|
| Long-Term Debt |
9
|
13
|
5
|
8
|
29
|
0
|
2
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
16
|
10
|
8
|
5
|
1
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
11
|
12
|
26
|
15
|
5
|
5
|
7
|
6
|
13
|
|
| Total Liabilities |
13
N/A
|
71
+436%
|
58
-18%
|
71
+22%
|
71
-1%
|
19
-73%
|
17
-13%
|
17
+3%
|
16
-5%
|
26
+57%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
136
|
183
|
303
|
448
|
509
|
664
|
723
|
785
|
861
|
939
|
|
| Additional Paid In Capital |
258
|
363
|
427
|
621
|
676
|
721
|
781
|
955
|
963
|
973
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
3
|
6
|
5
|
1
|
1
|
3
|
0
|
2
|
1
|
|
| Total Equity |
122
N/A
|
177
+46%
|
118
-34%
|
179
+52%
|
169
-6%
|
56
-67%
|
62
+11%
|
169
+175%
|
100
-41%
|
33
-66%
|
|
| Total Liabilities & Equity |
135
N/A
|
249
+84%
|
176
-29%
|
250
+42%
|
239
-4%
|
75
-69%
|
78
+5%
|
187
+138%
|
116
-38%
|
59
-49%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
5
|
8
|
9
|
15
|
17
|
21
|
116
|
235
|
237
|
265
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
